Edited by János Fischer and C. Robin Ganellin

Analogue-based Drug Discovery II Edited by János Fischer and C. Robin Ganellin

Analogue-based Drug Discovery II



DOCKET

Δ

WILEY-VCH Verlag GmbH & Co. KGaA

LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

The Editors

Prof. Dr. János Fischer

Richter Plc Gyömröi ut 30 1103 Budapest Hungary

Prof. Dr. C. Robin Ganellin

University College London Department of Chemistry 20 Gordon Street London WC1H OAJ United Kingdom

Supported by

DOCKET

Δ

The International Union of Pure and Applied Chemistry (IUPAC) Chemistry and Human Health Devision PO Box 13757 Research Triangle Park, NC 27709-3757 USA All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No .: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at http://dnb.d-nb.de.

© 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Cover Design Adam Design, Weinheim Typesetting Thomson Digital, Noida, India Printing and Binding Strauss GmbH, Mörlenbach

Printed in the Federal Republic of Germany Printed on acid-free paper

ISBN: 978-3-527-32549-8

Contents

Preface XV Introduction XVII Abbreviations XXI

Part I General Aspects 1

1	Optimizing Drug Therapy by Analogues 3
	János Fischer, C. Robin Ganellin, John Proudfoot, and Erika M. Alapi
1.1	Introduction 3
1.2	Pharmacodynamic Characteristics 4
1.2.1	Potency 4
1.2.2	Improving the Ratio of Main Activity and Adverse Effects 5
1.2.2.1	Improving Selectivity Through Receptor Subtypes 6
1.2.2.2	Improving Selectivity Through Unrelated Receptors 7
1.2.2.3	Improving Selectivity by Tissue Distribution 7
1.2.2.4	Improving Selectivity of Nonreceptor-Mediated Effects 10
1.2.3	Improving the Physicochemical Properties with Analogues 10
1.2.4	Analogues to Reduce the Resistance to Anti-Infective Drugs 11
1.2.4.1	Antibiotics 11
1.2.4.2	Antifungal Drugs 12
1.2.4.3	Antiviral Drugs 12
1.2.5	Analogue Research in Resistance to Drug Therapies in Cancer
	Treatment 15
1.3	Pharmacokinetic Characteristics 15
1.3.1	Improving Oral Bioavailability 15
1.3.1.1	Improving Absorption 16
1.3.1.2	Improving Metabolic Stability 16
1.3.2	Drugs with a Long Duration of Action 17
1.3.3	Ultrashort-Acting Drugs 18
1.3.4	Decreasing Interindividual Pharmacokinetic Differences 20

1.3.5 Decreasing Systemic Activity 21

DOCKE

LARM

Δ

Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA. Weinheim

Find authenticated court documents without watermarks at docketalarm.com.

v

VI Contents

1.4	Drug Interactions 22
1.4.1	Decreasing Drug Interactions 22
1.4.2	Increasing Drug Interactions 23
1.5	Summary 23
	References 24
2	Standalone Drugs 29
	János Fischer, C. Robin Ganellin, Arun Ganesan, and John Proudfoot
2.1	Acetaminophen (Paracetamol) 30
2.2	Acetylsalicylic Acid (Aspirin) 33
2.3	Aripiprazole 35
2.3.1	First Generation "Typical" Antipsychotic Drugs (Other Names:
	Neuroleptics, Conventional Antipsychotics) 36
2.3.2	Second-Generation "Atypical" Antipsychotic Drugs 37
2.3.3	A New Approach: Aripiprazole, a Dopamine Partial Agonist 38
2.4	Bupropion 39
2.5	Ezetimibe 42
2.6	Lamotrigine 46
2.7	Metformin 47
2.8	Topiramate 49
2.9	Valproate 51
2.10	Summary 52
	References 53
3	Application of Molecular Modeling in Analogue-Based
	Drug Discovery 61
	György G. Ferenczy
3.1	Introduction 61
3.2	Cilazapril: An ACE Inhibitor 62
3.3	Atorvastatin: A HMG-CoA Reductase Inhibitor 66
3.4	PDE4 Inhibitors 70
3.5	GPIIb/IIIa Antagonists 73
3.6	HIV Protease Inhibitors 74
3.7	Epilogue 79
	References 79
4	Issues for the Patenting of Analogues 83
	Stephen C. Smith
4.1	Introduction 83
4.2	Patents: Some Fundamentals 84
4.3	Patentability 85
4.4	Important Elements of the International Patent System 86
4.5	Priority 87
4.6	Novelty 88
4.7	Inventive Step: Nonobviousness 90
0.0052200	1998 - Million Market Barton and Barton and Barton and Barton and Barton and Barton and Andreas and Andreas and

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.